BI 836826: Clinical Trials

4 completed, 1 terminated, 1 withdrawn. 5 Phase 1, 1 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	5	Completed 3, Terminated 1, Withdrawn 1
Phase 2	1	Completed 1

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
This Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With Venetoclax Venetoclax, BI 836826 - Leukemia, Lymphocytic, Chronic, B-Cell	Phase 1	Withdrawn	Boehringer Ingelheim		2018-01-17	2018-01-09
Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib BI 836826, Ibrutinib - Leukemia, Lymphocytic, Chronic, B-Cell	Phase 1	Completed	Boehringer Ingelheim	7	2016-06-23	2020-09-29
To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCL BI 836826, GemOx, Rituximab - Lymphoma, Large B-Cell, Diffuse	Phase 2	Completed	Boehringer Ingelheim	21	2016-01-28	2019-06-17
Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia Idelalisib, BI 836826 - Chronic Lymphocytic Leukemia (CLL)	Phase 1	Terminated	Gilead Sciences	2	2015-12-29	2020-11-25
BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) BI 836826 - Lymphoma, Non-Hodgkin	Phase 1	Completed	Boehringer Ingelheim	48	2011-08-01	2020-08-11
BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL) BI 836826 - Leukemia, Lymphocytic, Chronic, B-Cell	Phase 1	Completed	Boehringer Ingelheim	37	2011-02-11	2020-08-20

Belgium (2) · France (2) · Germany (2) · United States (2) · Italy (1) · South Korea (1) · Spain (1)

2014 (2)